Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D In 2010: No Reference Pricing, More CMS Scrutiny Of Formulary Edits

Executive Summary

The last CMS 1draft "call letter" to Medicare Part D contractors to be issued under the current administration emphasizes familiar themes - concern with information transparency and ensuring appropriate access to drugs - and includes little in the way of drug coverage policy changes

You may also be interested in...



More Resources, Earlier Contact Would Improve Payer-Pharma Relationships

Biopharma companies could build stronger relationships with payers by adding resources and establishing earlier contacts with them, Cutting Edge Information concludes in a study on pharma's efforts to secure market access for products

More Resources, Earlier Contact Would Improve Payer-Pharma Relationships

Biopharma companies could build stronger relationships with payers by adding resources and establishing earlier contacts with them, Cutting Edge Information concludes in a study on pharma's efforts to secure market access for products

PhRMA Targets High Cost-Sharing For Drugs In Comments To CMS

The Pharmaceutical Research and Manufacturers of America is highlighting the negative impact high cost-sharing can have on patient access to drugs, most recently in comments on the draft 2010 "call letter" for Part D plans

Related Content

Topics

UsernamePublicRestriction

Register

PS050567

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel